Mel-Mont Medical

Mel-Mont Medical is a molecular diagnostics company focused on preserving life through early detection and prevention of HPV-related cancers. The company develops patented and clinically proven non-invasive self-sampling devices combined with proprietary comprehensive molecular testing to improve health outcomes. Mel-Mont's team of scientists and molecular biologists develops technologies that identify active infections of High-Risk Human Papilloma Virus at early stages. The product portfolio includes medical devices for HR-HPV cancer prevention, in vitro diagnostics through its PreTect division with an ISO 13485-certified HPV-mRNA molecular laboratory service, and sample preparation reagents for molecular testing. The company follows a rigorous six-step development process from idea creation through market launch with techno-surveillance. Founded in 2014, headquartered in Doral, United States, The company has raised $10.2M at the Series A stage..